Bone loss in perimenopausal women: a longitudinal study.
A longitudinal evaluation of bone mineral density (BMD) and metabolism was performed in premenopausal women. During the 2-year observation period, the menstrual pattern, plasma estradiol and FSH levels as well as the values of bone markers and BMD did not show any significant modification in a group of eumenorrhoic women (n = 37). Conversely, in age-matched oligomenorrhoic women (n = 37) a significant (P < 0.05) increase in the cycle length with a concomitant significant (P < 0.05) increase in circulating plasma FSH and parallel decrease of plasma estradiol levels (P < 0.05) was evident. In this group a significant (P < 0.05) increase in both urinary excretion of OH-P/Cr and plasma BGP levels paralleled a significant (P < 0.05) decrease in radial BMD. These data suggest that premenopausal impairment of ovarian function can lead to a bone loss in a significant proportion of women in which prevention should be considered before menopause.
Gambacciani
M
M
Department of Obstetrics and Gynecology, University of Pisa, Italy.
Spinetti
A
A
Taponeco
F
F
Cappagli
B
B
Maffei
S
S
Manetti
P
P
Piaggesi
L
L
Fioretti
P
P
D000328:Adult; D015519:Bone Density / Q000502:physiology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D006909:Hydroxyproline / Q000097:blood; D008137:Longitudinal Studies; D008598:Menstruation / Q000502:physiology; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000175:diagnosis / Q000503:physiopathology / Q000517:prevention & control*; D011237:Predictive Value of Tests; D017697:Premenopause / Q000502:physiology*; D012016:Reference Values; D012307:Risk Factors
D004958:Estradiol; D005640:Follicle Stimulating Hormone; D006909:Hydroxyproline